Monoclonal Antibody Developability is a pharmaceutical assessment framework that evaluates the suitability of monoclonal antibodies for clinical and commercial development based on their biophysical, biochemical, and pharmacokinetic properties.
127
Publications
5.6K
Citations
858
Authors
245
Institutions
Publications per year
2017–2026
52
Parents
Publications
127
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
Emanuele Andreano, Emanuele Nicastri, Ida Paciello et al. · Cell · 2021 · 239 citations · Full text
Predicting Antibody Developability Profiles Through Early Stage Discovery Screening
Marc Bailly, Carl Mieczkowski, Veronica Juan et al. · mAbs · 2020 · 223 citations · Full text
1–5 of 127
Authors
858
- LL
6
h-index
- CX
5
h-index
- HK
5
h-index
- JM
4
h-index
- YX
3
h-index
1–5 of 858
Institutions
245
Jiangnan University
Wuxi, China
5 h-index
22 publications
663 citations
Pfizer (United States)
New York, United States
5 h-index
27 publications
1.1K citations
State Key Laboratory of Food Science and Technology
Wuxi, China
5 h-index
27 publications
808 citations
AbbVie (United States)
North Chicago, United States
4 h-index
9 publications
179 citations
Tufts University
Medford, United States
4 h-index
4 publications
126 citations
Merck & Co., Inc., Rahway, NJ, USA (United States)
Rahway, United States
3 h-index
27 publications
2.2K citations
Amgen (United States)
Thousand Oaks, United States
3 h-index
56 publications
1.6K citations
Tufts Medical Center
Boston, United States
3 h-index
3 publications
100 citations
1–8 of 245
Venues
- mAbs
24 publications · 1.6K citations
21
h-index
- Journal of Immunological Methods
9 publications · 321 citations
9
h-index
- Biochemical and Biophysical Research Communications
BBRC · 3 publications · 69 citations
3
h-index
- Journal of Pharmaceutical Sciences
2 publications · 259 citations
3
h-index
- Food Chemistry
2 publications · 58 citations
2
h-index
1–5